{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T11:08:16Z","timestamp":1773832096796,"version":"3.50.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100014422","name":"Eli Lilly Japan K.K.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014422","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100012351","name":"Mitsubishi Tanabe Pharma Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012351","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s13300-025-01837-1","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T11:25:31Z","timestamp":1768821931000},"page":"391-410","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Weight Loss Outcomes by Obesity Management Approaches in Japan: Descriptive Findings from the J-ORBIT Database Linked to Electronic Medical Records (J-ORBIT2)"],"prefix":"10.1007","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3035-4155","authenticated-orcid":false,"given":"Yushi","family":"Hirota","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4348-6118","authenticated-orcid":false,"given":"Seiji","family":"Nishikage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4459-2469","authenticated-orcid":false,"given":"Satoshi","family":"Osaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4618-7507","authenticated-orcid":false,"given":"Ambrish","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1568-9763","authenticated-orcid":false,"given":"Tomotaka","family":"Shingaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7956-5378","authenticated-orcid":false,"given":"Taisuke","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4228-1723","authenticated-orcid":false,"given":"Masamichi","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6111-3154","authenticated-orcid":false,"given":"Kengo","family":"Miyo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0432-4366","authenticated-orcid":false,"given":"Wataru","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"key":"1837_CR1","doi-asserted-by":"crossref","unstructured":"GBD 2021 Risk Factors Collaborators. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403(10440): 2162\u20132203.","DOI":"10.1016\/S0140-6736(24)00933-4"},{"key":"1837_CR2","doi-asserted-by":"crossref","unstructured":"GBD 2021 Adult BMI Collaborators. Global, regional, and national prevalence of adult overweight and obesity, 1990\u20132021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021. Lancet. 2025;405(10481):813\u201338.","DOI":"10.1016\/S0140-6736(25)00355-1"},{"issue":"11","key":"1837_CR3","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1161\/CIRCRESAHA.120.316101","volume":"126","author":"ME Piche","year":"2020","unstructured":"Piche ME, Tchernof A, Despres JP. Obesity phenotypes, diabetes, and cardiovascular diseases. Circ Res. 2020;126(11):1477\u2013500.","journal-title":"Circ Res"},{"issue":"2","key":"1837_CR4","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1093\/annonc\/mdr143","volume":"23","author":"K Matsuo","year":"2012","unstructured":"Matsuo K, Mizoue T, Tanaka K, et al. Association between body mass index and the colorectal cancer risk in Japan: pooled analysis of population-based cohort studies in Japan. Ann Oncol. 2012;23(2):479\u201390.","journal-title":"Ann Oncol"},{"key":"1837_CR5","unstructured":"Obesity and overweight. 2024. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight#:~:text=children%20and%20adolescents.-,Adults,than%20or%20equal%20to%2030. Accessed Mar 20, 2025."},{"issue":"8","key":"1837_CR6","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.2337\/dc10-2300","volume":"34","author":"M Chiu","year":"2011","unstructured":"Chiu M, Austin PC, Manuel DG, et al. Deriving ethnic-specific BMI cutoff points for assessing diabetes risk. Diabetes Care. 2011;34(8):1741\u20138.","journal-title":"Diabetes Care"},{"issue":"7","key":"1837_CR7","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1038\/sj.ijo.0803248","volume":"30","author":"T Kadowaki","year":"2006","unstructured":"Kadowaki T, Sekikawa A, Murata K, et al. Japanese men have larger areas of visceral adipose tissue than Caucasian men in the same levels of waist circumference in a population-based study. Int J Obes (Lond). 2006;30(7):1163\u20135.","journal-title":"Int J Obes (Lond)"},{"key":"1837_CR8","doi-asserted-by":"crossref","unstructured":"Examination Committee of Criteria for 'Obesity Disease' in Japan Society for the Study of Obesity; Japan Society for the Study of Obesity. New criteria for 'obesity disease' in Japan. Circ J. 2002;66(11):987\u201392.","DOI":"10.1253\/circj.66.987"},{"issue":"3","key":"1837_CR9","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1507\/endocrj.EJ23-0593","volume":"71","author":"W Ogawa","year":"2024","unstructured":"Ogawa W, Hirota Y, Miyazaki S, et al. Definition, criteria, and core concepts of guidelines for the management of obesity disease in Japan. Endocr J. 2024;71(3):223\u201331.","journal-title":"Endocr J"},{"key":"1837_CR10","unstructured":"The National Health and Nutrition Survey (NHNS) Japan. 2023. https:\/\/www.mhlw.go.jp\/content\/10900000\/001338334.pdf. Accessed 13 Feb 2025."},{"issue":"3","key":"1837_CR11","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1507\/endocrj.EJ23-0416","volume":"71","author":"W Ogawa","year":"2024","unstructured":"Ogawa W, Gupta P. The humanistic and societal impact of obesity in Japan: a targeted literature review. Endocr J. 2024;71(3):273\u201384.","journal-title":"Endocr J"},{"key":"1837_CR12","unstructured":"Guidelines for the management of obesity disease 2022 (in Japanese). 2022. https:\/\/www.jasso.or.jp\/data\/magazine\/pdf\/medicareguide2022_05.pdf. Accessed 23 Apr 2025."},{"issue":"9","key":"1837_CR13","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/S2213-8587(19)30084-1","volume":"7","author":"IJ Neeland","year":"2019","unstructured":"Neeland IJ, Ross R, Despr\u00e9s JP, et al. Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. Lancet Diabetes Endocrinol. 2019;7(9):715\u201325.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"1837_CR14","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S2213-8587(24)00316-4","volume":"13","author":"F Rubino","year":"2025","unstructured":"Rubino F,\u00a0Cummings DE, Eckel RH, et al. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol. 2025;13(3):221\u201362.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1837_CR15","doi-asserted-by":"publisher","unstructured":"Ogawa W, Shimomura I, Yamauchi T, Yokote K. Clinical obesity and Himan-sho (obesity disease): lessons from Japan's 25 years of experience toward a new era of obesity care. J Diabetes Investig. 2025. https:\/\/doi.org\/10.1111\/jdi.70178.","DOI":"10.1111\/jdi.70178"},{"key":"1837_CR16","unstructured":"Expanding options for tackling obesity in Japan. 2025. https:\/\/www.nature.com\/articles\/d42473-023-00332-0#:~:text=In%20February%202023%2C%20a%20different,part%20of%20a%20holistic%20approach.%E2%80%9D. Accessed 15 Jan 2025"},{"key":"1837_CR17","unstructured":"Eli Lilly Japan K.K. and Mitsubishi Tanabe Pharma Corporation. \u201cZepbound\u00ae\u201d, a long-acting GIP\/GLP-1 receptor agonist, approved for the chronic disease of \u201cobesity disease\u201d with multiple factors. Kobe and Osaka: Eli Lilly Japan K.K. and Mitsubishi Tanabe Pharma Corporation; 2024."},{"issue":"1","key":"1837_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13340-021-00551-0","volume":"13","author":"A Sasaki","year":"2022","unstructured":"Sasaki A,\u00a0Yokote K, Naitoh T, et al. Metabolic surgery in treatment of obese Japanese patients with type 2 diabetes: a joint consensus statement from the Japanese Society for Treatment of Obesity, the Japan Diabetes Society, and the Japan Society for the Study of Obesity. Diabetol Int. 2022;13(1):1\u201330.","journal-title":"Diabetol Int"},{"issue":"12","key":"1837_CR19","doi-asserted-by":"publisher","first-page":"6091","DOI":"10.1097\/MS9.0000000000001472","volume":"85","author":"N Aderinto","year":"2023","unstructured":"Aderinto N,\u00a0Olatunji G, Kokori E, Olaniyi P, Isarinade T, Yusuf IA.\u00a0Recent advances in bariatric surgery: a narrative review of weight loss procedures. Ann Med Surg (Lond). 2023;85(12):6091\u2013104.","journal-title":"Ann Med Surg (Lond)"},{"key":"1837_CR20","doi-asserted-by":"publisher","unstructured":"Shenoy A, Schulman AR. Advances in endobariatrics: past, present, and future. Gastroenterol Rep (Oxf). 2023;11:goad043 https:\/\/doi.org\/10.1093\/gastro\/goad043.","DOI":"10.1093\/gastro\/goad043"},{"issue":"6","key":"1837_CR21","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1111\/jdi.70021","volume":"16","author":"S Nishikage","year":"2025","unstructured":"Nishikage S, Hirota Y, Nakagawa Y, et al. Relation between obesity and health disorders as revealed by the J-ORBIT clinical information collection system directly linked to electronic medical records (J-ORBIT 1). J Diabetes Investig. 2025;16(6):1100\u201311.","journal-title":"J Diabetes Investig"},{"key":"1837_CR22","unstructured":"Japan Obesity Research Based on electronIc healTh record organization. Research structure. 2021. https:\/\/j-orbit.jp\/organization\/. Accessed 8 Jan 2025."},{"key":"1837_CR23","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2025.2486167","author":"T Tanaka","year":"2025","unstructured":"Tanaka T, Kojima T, Pathadka S, et al. Real-world cross-sectional study evaluating patient characteristics, disease burden, and treatment approaches in people with obesity disease in Japan. Curr Med Res Opin. 2025. https:\/\/doi.org\/10.1080\/03007995.2025.2486167.","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"1837_CR24","doi-asserted-by":"publisher","first-page":"e466","DOI":"10.1016\/j.orcp.2013.10.003","volume":"8","author":"A Muramoto","year":"2014","unstructured":"Muramoto A,\u00a0Matsushita M, Kato A, et al. Three percent weight reduction is the minimum requirement to improve health hazards in obese and overweight people in Japan. Obes Res Clin Pract. 2014;8(5):e466\u201375.","journal-title":"Obes Res Clin Pract"},{"key":"1837_CR25","unstructured":"Kojima T, Yoshino M, Artime E, Tanno K. Epidemiology landscape and impact of obesity disease in Japan: a retrospective cohort study using the Japan claims database of the IMPACT-O Study (P-1-1). In: Japan Diabetes Society\u201468th Annual Meeting, 29\u201331 May 2025, Okayama."},{"issue":"11","key":"1837_CR26","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.1111\/dom.15238","volume":"25","author":"K Chen","year":"2023","unstructured":"Chen K,\u00a0Shen Z, Gu W, et al. Prevalence of obesity and associated complications in China: a cross-sectional, real-world study in 15.8 million adults. Diabetes Obes Metab. 2023;25(11):3390\u20139.","journal-title":"Diabetes Obes Metab"},{"issue":"Suppl 1","key":"1837_CR27","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/dom.15012","volume":"25","author":"P Tian","year":"2023","unstructured":"Tian P,\u00a0Fu J, Li M, et al. Metabolic and bariatric surgery in China: a summary of the Greater China Metabolic and Bariatric Surgery Database and comparison with other international registry databases. Diabetes Obes Metab. 2023;25(Suppl 1):27\u201333.","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"1837_CR28","doi-asserted-by":"publisher","first-page":"5056","DOI":"10.1111\/dom.15836","volume":"26","author":"J Pearson-Stuttard","year":"2024","unstructured":"Pearson-Stuttard J, Holloway S, Sommer Matthiessen K, Thompson A, Capucci S.\u00a0Ten-year progression of obesity-related complications in a population with overweight and obesity in the UK: a retrospective open cohort study. Diabetes Obes Metab. 2024;26(11):5056\u201364.","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"1837_CR29","doi-asserted-by":"publisher","first-page":"5005","DOI":"10.1111\/dom.15914","volume":"26","author":"JP Bae","year":"2024","unstructured":"Bae JP, Nelson DR, Boye KS, Mather KJ. Prevalence of complications and co-morbidities in males and females with obesity: real-world insights from claims data analysis. Diabetes Obes Metab. 2024;26(11):5005\u201312.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"1837_CR30","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/ases.12836","volume":"14","author":"M Ohta","year":"2021","unstructured":"Ohta M, Kasama K, Sasaki A, et al. Current status of laparoscopic bariatric\/metabolic surgery in Japan: sixth nationwide survey by the Japan Consortium of Obesity and Metabolic Surgery. Asian J Endosc Surg. 2021;14(2):170\u20137.","journal-title":"Asian J Endosc Surg"},{"issue":"6","key":"1837_CR31","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1007\/s11695-019-03716-8","volume":"29","author":"ZJ Koh","year":"2019","unstructured":"Koh ZJ, Tai BC, Kow L, et al. Influence of Asian ethnicities on short- and mid-term outcomes following laparoscopic sleeve gastrectomy. Obes Surg. 2019;29(6):1781\u20138.","journal-title":"Obes Surg"},{"issue":"5","key":"1837_CR32","doi-asserted-by":"publisher","first-page":"678","DOI":"10.3803\/EnM.2024.2056","volume":"39","author":"K Han","year":"2024","unstructured":"Han K, Jung JH, Jeong SM, Kim MK. Epidemiology and trends of obesity and bariatric surgery in Korea. Endocrinol Metab (Seoul). 2024;39(5):678\u201385.","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"1","key":"1837_CR33","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/jdi.13631","volume":"13","author":"Y Seki","year":"2022","unstructured":"Seki Y, Kasama K, Yokoyama R, et al. Bariatric surgery versus medical treatment in mildly obese patients with type 2 diabetes mellitus in Japan: propensity score-matched analysis on real-world data. J Diabetes Investig. 2022;13(1):74\u201384.","journal-title":"J Diabetes Investig"},{"issue":"11","key":"1837_CR34","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13326","volume":"22","author":"NN Ahmad","year":"2021","unstructured":"Ahmad NN, Robinson S, Kennedy-Martin T, Poon JL, Kan H. Clinical outcomes associated with anti-obesity medications in real-world practice: a systematic literature review. Obes Rev. 2021;22(11):e13326.","journal-title":"Obes Rev"},{"issue":"3","key":"1837_CR35","volume":"14","author":"M Srinivasan","year":"2022","unstructured":"Srinivasan M, Thangaraj SR, Arzoun H, Thomas SS, Mohammed L.\u00a0The impact of bariatric surgery on cardiovascular risk factors and outcomes: a systematic review. Cureus. 2022;14(3):e23340.","journal-title":"Cureus"},{"issue":"2","key":"1837_CR36","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/dom.12798","volume":"19","author":"A Patkar","year":"2017","unstructured":"Patkar A, Fegelman E, R Kashyap S, et al. Assessing the real-world effect of laparoscopic bariatric surgery on the management of obesity-related comorbidities: a retrospective matched cohort study using a US claims database. Diabetes Obes Metab. 2017;19(2):181\u20138.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"1837_CR37","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s13300-023-01511-4","volume":"15","author":"S Shinde","year":"2024","unstructured":"Shinde S,\u00a0Thieu VT, Kwan AYM, Houghton K, Meyers J, Schapiro D. Impact of weight change on glycemic control and metabolic parameters in T2D: a retrospective US study based on real-world data. Diabetes Ther. 2024;15(2):409\u201326.","journal-title":"Diabetes Ther"},{"issue":"4","key":"1837_CR38","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1002\/bjs.11433","volume":"107","author":"P Singh","year":"2020","unstructured":"Singh P, Subramanian A, Adderley N, et al. Impact of bariatric surgery on cardiovascular outcomes and mortality: a population-based cohort study. Br J Surg. 2020;107(4):432\u201342.","journal-title":"Br J Surg"},{"issue":"7","key":"1837_CR39","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.soard.2018.02.012","volume":"14","author":"AD Miras","year":"2018","unstructured":"Miras AD, Kamocka A, Patel D, et al. Obesity surgery makes patients healthier and more functional: real world results from the United Kingdom National Bariatric Surgery Registry. Surg Obes Relat Dis. 2018;14(7):1033\u201340.","journal-title":"Surg Obes Relat Dis"},{"issue":"6","key":"1837_CR40","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1038\/s41366-021-00788-4","volume":"45","author":"CL Haase","year":"2021","unstructured":"Haase CL,\u00a0Lopes S, Olsen AH, Satylganova A, Schnecke V, McEwan P. Weight loss and risk reduction of obesity-related outcomes in 0.5 million people: evidence from a UK primary care database. Int J Obes (Lond). 2021;45(6):1249\u201358.","journal-title":"Int J Obes (Lond)"},{"issue":"9","key":"1837_CR41","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1111\/dom.15154","volume":"25","author":"KKF MedSci","year":"2023","unstructured":"MedSci KKF, Schnecke V, Haase CL, et al. Weight change and risk of obesity-related complications: a retrospective population-based cohort study of a UK primary care database. Diabetes Obes Metab. 2023;25(9):2669\u201379.","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"1837_CR42","doi-asserted-by":"publisher","first-page":"3125","DOI":"10.1111\/dom.15206","volume":"25","author":"K Fujihara","year":"2023","unstructured":"Fujihara K, Khin L, Murai K, et al. Relationship between the magnitude of body mass index reductions and remission in patients with type 2 diabetes in real world settings: analysis of nationwide patient registry in Japan (JDDM74). Diabetes Obes Metab. 2023;25(11):3125\u201335.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"1837_CR43","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1111\/jdi.12339","volume":"6","author":"H Iwahashi","year":"2015","unstructured":"Iwahashi H,\u00a0Noguchi M, Okauchi Y, Morita S, Imagawa A, Shimomura I. Extent of weight reduction necessary for minimization of diabetes risk in Japanese men with visceral fat accumulation and glycated hemoglobin of 5.6-6.4. J Diabetes Investig. 2015;6(5):553\u20139.","journal-title":"J Diabetes Investig"},{"issue":"6","key":"1837_CR44","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1159\/000442721","volume":"8","author":"V Yumuk","year":"2015","unstructured":"Yumuk V,\u00a0Tsigos C, Fried M, et al. European guidelines for obesity management in adults. Obes Facts. 2015;8(6):402\u201324.","journal-title":"Obes Facts"},{"issue":"1","key":"1837_CR45","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1159\/000496183","volume":"12","author":"D Durrer Schutz","year":"2019","unstructured":"Durrer Schutz D, Busetto L, Dicker D, et al. European practical and patient-centred guidelines for adult obesity management in primary care. Obes Facts. 2019;12(1):40\u201366.","journal-title":"Obes Facts"},{"issue":"15 Suppl","key":"1837_CR46","first-page":"S288","volume":"28","author":"MA Cornier","year":"2022","unstructured":"Cornier MA. A review of current guidelines for the treatment of obesity. Am J Manag Care. 2022;28(15 Suppl):S288\u201396.","journal-title":"Am J Manag Care"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-025-01837-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-025-01837-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-025-01837-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T08:22:18Z","timestamp":1773822138000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-025-01837-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1837"],"URL":"https:\/\/doi.org\/10.1007\/s13300-025-01837-1","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,19]]},"assertion":[{"value":"30 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yushi Hirota received payment or honoraria from Eli Lilly Japan K.K., Sanofi K.K., Abbott Japan LLC., Terumo Corp., Sumitomo Pharma Co. Ltd., Novo Nordisk Pharma Ltd., Medtronic Japan Co. Ltd., Dexcom Inc., Mitsubishi Tanabe Pharma Co., Daiichi Sankyo Co., Teijin Pharma Ltd., Sanwa Kagaku Kenkyusho Co., Novartis Pharma K.K., Kyowa Kirin Co. Ltd., Roche Diagnostics K.K., Kowa Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Nippon Boehringer Ingelheim Co. Ltd., LifeScan Japan K.K., Nipro Corp., and Mochida Pharmaceutical Co. Ltd.; and grants or contracts from Sumitomo Pharma Co. Ltd., Medtronic Japan Co. Ltd., Abbott Japan LLC., Nippon Boehringer Ingelheim Co. Ltd., and Kyowa Kirin Co. Ltd. Satoshi Osaga, Tomotaka Shingaki, and Taisuke Kojima are employees of Eli Lilly Japan K.K. and may own stock or stock options of Eli Lilly and Company. Ambrish Singh is an employee of Eli Lilly Services India Private Limited and may own stock or stock options of Eli Lilly and Company. Kengo Miyo received grants or contracts from Mitsubishi Electric Software Corp. and NEC Corp.; and donations from Ship Healthcare Holdings Inc., SoftBank Corp., and NEC Corp. Wataru Ogawa received lecture fees from Sumitomo Pharma Co. Ltd., Nippon Boehringer Ingelheim Co. Ltd., Abbott Japan, and Novo Nordisk Pharma Ltd.; grants or contracts from Noster Co. Ltd., Nippon Boehringer Ingelheim Co. Ltd., Eli Lilly Japan K.K., Sumitomo Pharma Co. Ltd., Novo Nordisk Pharma Ltd., Taisho Pharmaceutical Co. Ltd., Mochida Pharmaceutical Co. Ltd, and Kowa Co. Ltd; and payments or honoraria from Eli Lilly Japan K.K., Terumo Corp., Nippon Boehringer Ingelheim Co. Ltd., Kissei Pharmaceutical Co. Ltd., MSD K.K., Chugai Pharmaceutical Co. Ltd., Viatris Pharmaceuticals, LLC., Amgen K.K., Pfizer Japan Inc., Sanofi K.K., Abbott Japan LLC., Johnson & Johnson K.K., Kyowa Kirin Co. Ltd., Kowa Pharmaceutical Co. Ltd., Novo Nordisk Pharma Ltd., Sumitomo Pharma Co. Ltd., Takeda Pharmaceutical Co. Ltd., Astellas Pharma Inc., Mistubishi Tanabe Pharma Co., Eisai Co. Ltd., Taisho Pharmaceutical Co. Ltd., and Noster Inc.. Seiji Nishikage and Masamichi Ishii have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was conducted per ethical principles originating from the Declaration of Helsinki and was compliant with the Japanese \u201cEthical Guidelines for Medical and Biological Research Involving Human Subjects.\u201d The Ethics Committee of Kobe University Graduate School of Medicine approved this study on 22 April 2024 (approval number B240017). Individual informed consent was not required due to the study\u2019s retrospective and non-interventional nature. The IwOD received information regarding the study from the participating institution\u2019s website and retained the right to opt-out.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}